Ignite Creation Date:
2024-05-05 @ 5:22 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00442650
Status:
COMPLETED
Last Update Posted:
2016-11-21
First Post:
2007-02-28
Brief Title:
Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Study Overview
Official Title:
None
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Multicentre open label phase III study Subjects with moderate to severe psoriasis were given efalizumab subcutaneously once per week for the 12-week treatment period Assessments involved physical examination disease activity assessments clinical laboratory tests haematology blood chemistry and standard urinalysis evaluation of the Psoriasis Area and Severity Index PASI the Physicians Global Assessment PGA the Patients Global Psoriasis Assessment PGPA the SF-36 Health Survey and psoriatic body surface area BSA The 12-week treatment period was followed by a 12-week follow-up FU period during which other antipsoriatic medications were allowed The same assessments were also performed in the 12-week FU period
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None